Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analys...

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...

The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one...

For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...

Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...

Oil is crucial for every part of the Indian economy: From government to consumer, its price impacts spending by every stakeholder. So, till...

Artificial intelligence is often hailed as a game changer, but too many firms discover that their bold AI pilots collapse when their operat...

Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a qua...

Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue ...

Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batche...

As the market makes an attempt to move upward, there is a clear preference for sectors that are focused on the domestic market. Given this,...

Given the state of the market these days, it would be wise to be selective. Not only in terms of stocks, but also in terms of sectors. For ...

Now, there is nothing wrong with being bullish, because it has always paid to be bullish. Yes, one might argue that it has not paid in the ...

It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...

Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...

Government's Minimum Import Price (MIP) initiative to boost domestic drug makers faces a slow start. Despite setting price thresholds for k...